Last reviewed · How we verify
SGI-110 Dose Escalation
At a glance
| Generic name | SGI-110 Dose Escalation |
|---|---|
| Also known as | Guadecitabine |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Neutropenia
- Leukopenia
- Lymphopenia
- Nausea
- Anemia
- Fever
- Injection site reaction
- Anorexia
- Thrombocytopenia
- Constipation
- Fatigue or malaise
- Alkaline phosphatase increased
Key clinical trials
- Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (PHASE1)
- SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (PHASE1, PHASE2)
- SGI-110 in Combination With Carboplatin in Ovarian Cancer (PHASE2)
- Decitabine and Talazoparib in Untreated AML and R/R AML (PHASE1, PHASE2)
- Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer (PHASE1, PHASE2)
- Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer (PHASE1, PHASE2)
- SGI-110 Plus Durvalumab/Tremelimumab in SCLC (PHASE1)
- A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |